H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Neutral rating on Summit Therapeutics plc (NASDAQ: SMMT).The analyst commented: "OptiTROP-Lung06 raises ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments